Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090116 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00090116 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 400 participants.
The verdict
NCT00090116, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).
Interventions
- DRUG Neramexane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090116
The ClinicalTrials.gov registry entry for NCT00090116 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neramexane is the first listed.
NCT00090116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090116 about?
NCT00090116 is a clinical study titled "The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease". Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neram...
What is the current status of trial NCT00090116?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2003-03. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00090116?
The interventions under investigation include: Neramexane (DRUG).
Who is sponsoring clinical trial NCT00090116?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.